1
|
Takahashi N, Nakashima R, Nasu A, Hayashi M, Fujikawa H, Kawakami T, Eto Y, Kishimoto T, Fukuyama A, Ogasawara C, Kawano K, Fujiwara Y, Suico MA, Kai H, Shuto T. T 3 Intratracheal Therapy Alleviates Pulmonary Pathology in an Elastase-Induced Emphysema-Dominant COPD Mouse Model. Antioxidants (Basel) 2023; 13:30. [PMID: 38247455 PMCID: PMC10812479 DOI: 10.3390/antiox13010030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2023] [Revised: 12/10/2023] [Accepted: 12/14/2023] [Indexed: 01/23/2024] Open
Abstract
Chronic obstructive pulmonary disease (COPD) is a complex pulmonary condition characterized by bronchitis, emphysema, and mucus stasis. Due to the variability in symptoms among patients, traditional approaches to treating COPD as a singular disease are limited. This led us to focus on phenotype/endotype classifications. In this study, we explore the potential therapeutic role of thyroid hormone (T3) by using mouse models: emphysema-dominant elastase-induced COPD and airway-dominant C57BL/6-βENaC-Tg to represent different types of the disease. Here, we showed that intratracheal T3 treatment (40, 80 μg/kg, i.t., every other day) resulted in significant improvements regarding emphysema and the enhancement of respiratory function in the elastase-induced COPD model. T3-dependent improvement is likely linked to the up-regulation of Ppargc1a, a master regulator of mitochondrial biogenesis, and Gclm, a factor associated with oxidative stress. Conversely, neither short- nor long-term T3 treatments improved COPD pathology in the C57BL/6-βENaC-Tg mice. Because the up-regulation of extrathyroidal T3-producing enzyme Dio2, which is also considered a marker of T3 requirement, was specifically observed in elastase-induced COPD lungs, these results demonstrate that exogenous T3 supplementation may have therapeutic potential for acute but not chronic COPD exacerbation. Moreover, this study highlights the relevance of considering not only COPD phenotypes but also COPD endotypes (expression levels of Ppargc1a and/or Dio2) in the research and development of better treatment approaches for COPD.
Collapse
Affiliation(s)
- Noriki Takahashi
- Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan; (N.T.); (A.N.); (M.H.); (H.F.); (T.K.); (T.K.); (A.F.); (C.O.); (K.K.); (M.A.S.); (H.K.)
- Program for Leading Graduate Schools “HIGO (Health Life Science: Interdisciplinary and Global Oriented) Program”, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan
| | - Ryunosuke Nakashima
- Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan; (N.T.); (A.N.); (M.H.); (H.F.); (T.K.); (T.K.); (A.F.); (C.O.); (K.K.); (M.A.S.); (H.K.)
| | - Aoi Nasu
- Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan; (N.T.); (A.N.); (M.H.); (H.F.); (T.K.); (T.K.); (A.F.); (C.O.); (K.K.); (M.A.S.); (H.K.)
- Program for Leading Graduate Schools “HIGO (Health Life Science: Interdisciplinary and Global Oriented) Program”, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan
| | - Megumi Hayashi
- Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan; (N.T.); (A.N.); (M.H.); (H.F.); (T.K.); (T.K.); (A.F.); (C.O.); (K.K.); (M.A.S.); (H.K.)
| | - Haruka Fujikawa
- Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan; (N.T.); (A.N.); (M.H.); (H.F.); (T.K.); (T.K.); (A.F.); (C.O.); (K.K.); (M.A.S.); (H.K.)
- Program for Leading Graduate Schools “HIGO (Health Life Science: Interdisciplinary and Global Oriented) Program”, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan
| | - Taisei Kawakami
- Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan; (N.T.); (A.N.); (M.H.); (H.F.); (T.K.); (T.K.); (A.F.); (C.O.); (K.K.); (M.A.S.); (H.K.)
| | - Yuka Eto
- Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan; (N.T.); (A.N.); (M.H.); (H.F.); (T.K.); (T.K.); (A.F.); (C.O.); (K.K.); (M.A.S.); (H.K.)
| | - Tomoki Kishimoto
- Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan; (N.T.); (A.N.); (M.H.); (H.F.); (T.K.); (T.K.); (A.F.); (C.O.); (K.K.); (M.A.S.); (H.K.)
| | - Ayami Fukuyama
- Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan; (N.T.); (A.N.); (M.H.); (H.F.); (T.K.); (T.K.); (A.F.); (C.O.); (K.K.); (M.A.S.); (H.K.)
| | - Choyo Ogasawara
- Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan; (N.T.); (A.N.); (M.H.); (H.F.); (T.K.); (T.K.); (A.F.); (C.O.); (K.K.); (M.A.S.); (H.K.)
| | - Keisuke Kawano
- Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan; (N.T.); (A.N.); (M.H.); (H.F.); (T.K.); (T.K.); (A.F.); (C.O.); (K.K.); (M.A.S.); (H.K.)
| | - Yukio Fujiwara
- Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1, Honjo, Kumamoto Chuo-ku, Kumamoto 860-8556, Japan;
| | - Mary Ann Suico
- Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan; (N.T.); (A.N.); (M.H.); (H.F.); (T.K.); (T.K.); (A.F.); (C.O.); (K.K.); (M.A.S.); (H.K.)
- Global Center for Natural Resources Sciences, Faculty of Life Sciences, Kumamoto University, 5-1 Oe-Honmachi, Chuo-ku, Kumamoto 862-0973, Japan
| | - Hirofumi Kai
- Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan; (N.T.); (A.N.); (M.H.); (H.F.); (T.K.); (T.K.); (A.F.); (C.O.); (K.K.); (M.A.S.); (H.K.)
- Global Center for Natural Resources Sciences, Faculty of Life Sciences, Kumamoto University, 5-1 Oe-Honmachi, Chuo-ku, Kumamoto 862-0973, Japan
| | - Tsuyoshi Shuto
- Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan; (N.T.); (A.N.); (M.H.); (H.F.); (T.K.); (T.K.); (A.F.); (C.O.); (K.K.); (M.A.S.); (H.K.)
- Global Center for Natural Resources Sciences, Faculty of Life Sciences, Kumamoto University, 5-1 Oe-Honmachi, Chuo-ku, Kumamoto 862-0973, Japan
| |
Collapse
|